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Objectives: Patients with Alzheimer's disease psychosis (ADP) commonly experience
concomitant agitation and aggression. We investigated whether a reduction in ADP
following pimavanserin treatment conferred a reduction in associated agitation and
aggression.
Methods: ACP-103-019 was a 12-week, randomized, double-blind, placebo-
controlled study that evaluated the efficacy of pimavanserin (34 mg) in reducing
psychotic symptoms in patients with ADP. The primary endpoint was change from
baseline in Neuropsychiatric Inventory-Nursing Home Version-Psychosis Score (NPI-
NH-PS) at week six. A post hoc analysis examined whether there was a greater
reduction in agitation and aggression (NPI-NH domain C [agitation/aggression] and
Cohen-Mansfield Agitation Inventory-Short Form [CMAI-SF]) in pimavanserin-
treated patients who experienced a reduction of hallucinations and delusions (psy-
chosis responders defined as ≥50% reduction from baseline in NPI-NH-PS, week six)
when compared with those who did not (nonresponders).
Results: Pimavanserin-treated patients with ≥50% response in psychotic symptoms
(n = 44) showed a greater improvement in agitation and aggression symptoms on the
NPI-NH domain C (week six, least squares mean [LSM] difference = −3.64, t = −4.69,
P < .0001) and the CMAI-SF (week six, LSM difference = −3.71, t = −2.01, P = .0483)
than nonresponders (n = 32). Differences between psychosis responders and nonre-
sponders were also observed in patients with more severe agitation and aggression
at baseline on the NPI-NH domain C (responders, n = 26; nonresponders, n = 13;
week six, LSM difference = −3.03, t = −2.44, P = .019).
Conclusions: Patients with ADP, who show improvement in psychotic symptoms
after pimavanserin treatment, also experience an improvement in concomitant agita-
tion and aggression.
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1 | INTRODUCTION
More than 45 million people worldwide are living with dementia, the
majority of whom have Alzheimer's disease (AD).1 While AD is com-
monly thought of as a memory disorder, behavioral and psychological
symptoms of dementia are nearly universal and include psychotic
symptoms.1-3 More than half of patients with AD will experience psy-
chosis during their illness.4-6 Hallucinations and delusions are frequently
distressing to the individual and their caregivers and are associated with
worse disease outcomes relative to AD patients without psychosis,4 includ-
ing accelerated cognitive decline,7,8 more rapid progression of functional
impairment,9 increased hospital admissions,10 earlier admission to institu-
tional care,8,9 and increased mortality.9,11 In addition, psychotic symptoms
are often antecedent to or comorbid with other neuropsychiatric symp-
toms like agitation, aggression, and depression, further adding to the impact
on the individual and others making Alzheimer's disease psychosis (ADP)
more difficult to treat.2,5,12
Currently, no treatments have been approved for ADP.13 The
modest benefits provided by anxiolytics or typical/atypical antipsy-
chotics that clinicians prescribe to mitigate hallucinations and delu-
sions in ADP are associated with considerable adverse effects, such as
accelerated cognitive decline and increased short-term mortality in
elderly populations.14-16
Disruptive behaviors and significant impairments in interpersonal
relationships and social functioning make agitation and aggression
one of the most difficult symptoms to treat.17,18 However, the under-
lying causes and mechanisms of agitation and aggression are multifac-
eted and not well understood.13,17 Agitation may be due to direct
underlying biological or environmental factors (psychosocial stress or
intercurrent medication) or may be a consequence of psychosis, major
depressive disorder, or other mood or psychiatric disturbances.16,17 It
is unclear whether the symptoms of agitation and aggression associ-
ated with ADP are related to psychosis or are independent behavioral
symptoms that need to be treated separately. To optimize the treat-
ment of ADP, a greater understanding of how the treatment of psy-
chosis affects agitation and aggression symptoms is needed.
Pimavanserin is currently approved by the United States Food
and Drug Administration (FDA) for the treatment of hallucinations
and delusions associated with Parkinson's disease psychosis
(PDP).19,20 The positive effect of pimavanserin in improving psychotic
symptoms in ADP was also seen in a randomized, double-blind,
placebo-controlled trial.15,21 After 6 weeks of pimavanserin treatment,
51% of patients with ADP, treated with pimavanserin, showed ≥50%
improvement compared with baseline in symptoms of psychosis (hal-
lucinations and delusions) on the Neuropsychiatric Inventory-Nursing
Home Version-Psychosis Score (NPI-NH-PS).15
While the therapeutic benefit of pimavanserin in improving hallucina-
tions and delusions is promising in patients with ADP, treating agitation
and aggression symptoms in this group is also an important component of
treatment. The goal of this post hoc analysis was to investigate whether
decreases in the severity of a patient's hallucinations and delusions while
receiving pimavanserin were associated with a reduction in the severity
and frequency of the patient's agitation and aggression.
2 | METHODS
2.1 | Study design
Data were collected as a part of the study, ACP-103-019
(NCT02035553), a 12-week, randomized, double-blind, placebo-
controlled phase 2 trial conducted in nursing home patients with
ADP. Study design and primary results of the study as well as out-
comes in patients with more severe psychosis symptoms have been
previously published.15,21 The primary objective of the study was to
assess the efficacy of pimavanserin in attenuating ADP-related symp-
toms, as assessed by NPI-NH-PS, after 6 weeks of treatment.
All procedures were conducted in accordance with the Declara-
tion of Helsinki and the International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use, Good
Clinical Practices, and the United States Code of Federal Regulations.
Participants were given 3 weeks of brief psychosocial therapy22 and
were then randomly assigned to receive either pimavanserin 34 mg or
placebo administered orally once daily, with stratification by baseline
Mini-Mental State Examination (MMSE) total score and NPI-NH-PS.23
At baseline and after 2, 4, 6, 9, and 12 weeks of pimavanserin treat-
ment or placebo, the NPI-NH24 and the Cohen-Mansfield Agitation
Inventory-Short Form (CMAI-SF)25 were administered.
2.2 | Patient eligibility
Nursing home patients, 50 years or older, were eligible to participate
if they met National Institute of Neurological and Communicative Dis-
orders and Stroke-Alzheimer's Disease and Related Disorders Associa-
tion (NINCDS-ADRDA) criteria for possible or probable AD26 and
exhibited psychotic symptoms severe enough to warrant treatment
with an NPI-NH score of ≥4 in either the delusions or hallucinations
domain or a combined score of ≥6 for both measures (delusions + hal-
lucinations). Additional inclusion and exclusion criteria have been pub-
lished previously.15
Key points
• Patients with ADP commonly experience concomitant
agitation and aggression.
• Patients with ADP who respond to the therapeutic bene-
fit of pimavanserin on psychosis symptoms also experi-
ence improvement in agitation and aggression compared
with nonresponders.
• Patients with ADP and severe agitation and aggression at
baseline who respond to the therapeutic benefit of
pimavanserin on psychosis symptoms also show greater
improvements in agitation and aggression than
nonresponders.
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2.3 | Post hoc analysis
The effect of pimavanserin on agitation and aggression symptoms
was compared in patients responsive and nonresponsive to
pimavanserin's treatment of psychotic symptoms. Psychosis
responders were defined as patients who exhibited ≥50% improve-
ment from baseline in NPI-NH-PS at week six; patients who received
pimavanserin but did not meet these improvement criteria were con-
sidered nonresponders.
An additional analysis of psychosis responders vs nonresponders
was conducted in the subgroup of pimavanserin-treated patients
exhibiting more severe agitation and aggression symptoms at baseline,
as demonstrated by an NPI-NH agitation/aggression subscale score
higher than the midpoint (≥6).
2.4 | Statistical analysis
Baseline characteristics of week six psychosis responders and nonre-
sponders were compared using a t-test for continuous parameters or
chi-squared test for categorical parameters.
A mixed-effects model for repeated measures was used to
determine whether the effect of pimavanserin on agitation and
aggression symptoms was related to the therapeutic benefit of
pimavanserin on psychosis symptoms. The mean change from base-
line in the NPI-NH domain C (agitation and aggression subscale) or
the CMAI-SF was analyzed as the dependent variable. The model
included fixed effects of baseline MMSE score (<6 vs ≥6), baseline
psychosis score (<12 vs ≥12), baseline score of the dependent vari-
able (NPI-NH domain C or CMAI-SF score), group (responder vs non-
responder), study visit (weeks 2, 4, 6, 9, and 12), and group-by-study
visit interaction. Group differences are reported as the least square
(LS) mean (standard error [SE]) change from baseline for each mea-
sure. The association between change from baseline scores in the
NPI-NH-PS and change from baseline in agitation and aggression
symptoms as measured by both the NPI-NH domain C scores and
the CMAI-SF scores at week six was also analyzed using a Spe-
arman's correlation test. All analyses were conducted at the 5% level
of significance using two-sided tests.
3 | RESULTS
3.1 | Patients
In the study, 181 patients from 133 care homes across the United King-
dom (UK) were randomized to receive pimavanserin (n = 90) or placebo
(n = 91). Efficacy analyses included all patients who received at least
one dose of pimavanserin and completed the NPI-NH at baseline and
at least one postbaseline study visit (pimavanserin, n = 87). At baseline,
patients had an overall mean (standard deviation [SD]) score on the
NPI-NH domain C of 4.7 (3.9) and an overall mean (SD) score on the
CMAI-SF of 28.6 (8.8) (Table 1). More severe baseline agitation/
aggression symptoms, defined by a score of ≥6 on the NPI-NH domain
C subscale, were observed in 43 of 87 (49.4%) pimavanserin-treated
patients and 42 of 91 (46.2%) placebo-treated patients.
3.2 | Overall changes in agitation and aggression
symptoms
As previously reported, in the overall study population, pimavanserin
treatment did not improve agitation and aggression symptoms (rela-
tive to placebo) based on either the NPI-NH domain C (pimavanserin:
n = 76; LS mean change from baseline [SE], −1.13 [0.414]; placebo:
n = 81; LS mean change [SE], −0.47 [0.401]; difference = −0.66, t =
−1.14; P = .2544) or the CMAI-SF (pimavanserin: n = 77; LS mean
change [SE], −2.07 [0.846]; placebo: n = 81; LS mean change [SE],
−2.36 [0.825]; difference = 0.30, t = 0.25; P = .8031).15
3.3 | Changes in agitation and aggression
symptoms in psychosis responders
At the study's primary-efficacy endpoint of 6 weeks, 44 of 87 patients
(50.6%) were defined as psychosis responders based on exhibiting
a ≥50% reduction on the NPI-NH-PS. Data were not available for
11 patients. Baseline symptoms of agitation and aggression were
comparable for psychosis responders and nonresponders, with mean
(SE) NPI-NH domain C scores of 5.57 (0.658) for psychosis responders
and 4.47 (0.648) for nonresponders and mean (SE) CMAI-SF scores of
28.57 (1.312) for psychosis responders and 28.75 (1.665) for nonre-
sponders (Table 1).
At the study's primary-efficacy endpoint of week six, psycho-
sis responders exhibited a significantly greater improvement in
NPI-NH domain C score (LS mean change [SE], −2.85 [0.497])
than nonresponders (LS mean change [SE], 0.79 [0.584]; differ-
ence = −3.64; t = −4.69; 95% CI, −5.19 to −2.10, P < .0001)
(Figure 1A). Similarly, psychosis responders exhibited a signifi-
cantly greater reduction from baseline to week six on the CMAI-
SF (LS mean change [SE], −3.73 [1.185]) than nonresponders
(LS mean change [SE], −0.02 [1.390]; difference = −3.71; t =
−2.01; 95% CI, −7.38 to −0.03; P = .0483) (Figure 1B).
In the overall study population, change from baseline on the NPI-
NH-PS at week six was strongly correlated with the change from
baseline in agitation and aggression symptoms, as measured by both
the NPI-NH domain C (n = 157; r = 0.29, P = .0002) and the CMAI-SF
(n = 156; r = 0.33, P < .0001).
3.4 | Changes in symptoms of agitation and
aggression in patients with more severe baseline
symptoms
Among pimavanserin-treated patients who had a week 6 NPI-NH
domain C response (n = 39), severe agitation and aggression (NPI-NH
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domain C score ≥ 6) were observed at baseline in 26 psychosis
responders and 13 nonresponders (Table 1). Psychosis responders and
nonresponders in this subset of patients exhibited comparable baseline
mean (SE) NPI-NH domain C scores (psychosis responders: 8.69 [0.489];
nonresponders: 8.00 [0.784]) and baseline mean (SE) CMAI-SF scores
(psychosis responders: 32.38 [1.724]; nonresponders: 35.31 [1.848]).
At the study's primary-efficacy endpoint of week six, this subset
of psychosis responders exhibited a significantly greater reduction
on the NPI-NH domain C score (LS mean change [SE], −4.86 [0.688])
than nonresponders (LS mean change [SE], −1.83 [0.993]; differ-
ence = −3.03; t = −2.44; 95% CI, −5.54 to −0.52; P = .0190) (Fig-
ure 2A). A statistical difference was not observed at 6 weeks on the
CMAI-SF; however, this subset of psychosis responders appeared to
show a numerically greater reduction compared with nonresponders
(LS mean change [SE], −6.57 [1.827] vs −1.75 [2.618], differ-
ence = −4.82, t = −1.47; P = .1484) (Figure 2B).
In patients with severe agitation and aggression at baseline,
change from baseline on the NPI-NH-PS at week six was correlated





overall (n = 87)
Pimavanserin






Female, n (%) 73 (80.2) 71 (81.6) 36 (81.8) 29 (90.6) .281
Age, mean (min, max) (years) 86.1 (64, 99) 85.6 (68, 99) 85.5 (70, 95) 86.8 (70, 99) .403
NPI-NH-PS, mean (SD) 10.0 (5.6) 9.5 (4.8) 11.0 (5.0) 8.6 (4.6) .036
NPI-NH-PS ≥12, n (%) 30 (33.0) 27 (31.0) 21 (47.7) 6 (18.8) .009
NPI-NH domain C (agitation/
aggression), mean (SD)
4.5 (3.8) 4.9 (4.0) 5.6 (4.4) 4.5 (3.7) .250
NPI-NH domain C (agitation/
aggression) ≥6, n (%)
42 (46.2) 43 (49.4) 26 (59.1) 13 (40.6) .112
CMAI-SF total score, mean
(SD)
28.9 (8.9) 28.3 (8.7) 28.6 (8.7) 28.8 (9.4) .931
MMSE, mean (SD) 9.8 (5.0) 10.3 (5.4) 10.7 (5.6) 10.0 (5.0) .562
MMSE <6, n (%)a 15 (17.6) 18 (21.4) 7 (17.1) 7 (21.9) .605
Abbreviations: CMAI-SF, Cohen-Mansfield Agitation Inventory-Short Form; MMSE, Mini-Mental State Examination; NPI-NH-PS, Neuropsychiatric
Inventory-Nursing Home Version-Psychosis Score; SD, SD.
aNumber of subjects with non-missing data used as the denominator for calculating percentages with each treatment group (Placebo = 85;
Pimavanserin = 84; Total = 169).
bt test for continuous variables, chi-square test for categorical variables.
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F IGURE 1 Changes in agitation and aggression symptoms among psychosis responders vs nonresponders as assessed by (A) NPI-NH domain
C or (B) CMAI-SF. *P < .05. Δ = difference in LS mean change from baseline ((Responders LS mean change from baseline) − (Nonresponders LS
mean change from baseline)). BL, baseline; CMAI-SF, Cohen-Mansfield Agitation Inventory-Short Form; LS, least square; NPI-NH-PS,
Neuropsychiatric Inventory-Nursing Home Version-Psychosis Score; NR, nonresponders; R, responders; SE, standard error
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with the change from baseline in agitation and aggression symptoms,
as measured by both the NPI-NH domain C (n = 77; r = 0.23,
P = .048) and the CMAI-SF (n = 77; r = 0.26, P = .021).
3.5 | Safety
Pimavanserin was well tolerated in both psychosis responders and
nonresponders. Adverse events occurred in 44 (100%) psychosis
responders and 30 (93.8%) nonresponders; serious adverse events
occurred in 4 (9.1%) psychosis responders and 7 (21.9%) nonre-
sponders. Rates of individual adverse events were similar between
psychosis responders and nonresponders (Table 2).
4 | DISCUSSION
This post hoc responder analysis suggests improvements in psychotic
symptoms in patients receiving pimavanserin treatment were associ-
ated with an improvement in agitation and aggression symptoms.
Patients showing ≥50% improvement from baseline in psychotic
symptoms after 6 weeks of pimavanserin treatment exhibited a
greater improvement in agitation and aggression symptoms than non-
responders. This effect was observed on two distinct measures, the
NPI-NH domain C score and the CMAI-SF score.
In patients with ADP, experiencing severe agitation and aggres-
sion symptoms at baseline (baseline NPI-NH domain C score ≥ 6), the
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F IGURE 2 Changes in agitation and aggression symptoms among psychosis responders with more severe symptoms of agitation and
aggression at baseline as assessed by (A) NPI-NH domain C or (B) CMAI-SF. *P < .05. Δ = difference in LS mean change from baseline
([responders LS mean change from baseline] – [nonresponders LS mean change from baseline]). BL, baseline; CMAI-SF, Cohen-Mansfield
Agitation Inventory-Short Form; LS, least square; NPI-NH-PS, Neuropsychiatric Inventory-Nursing Home Version-Psychosis Score; NR,
nonresponders; R, responders; SE, standard error






Summary of adverse events, n (%)
Any adverse event 44 (100) 30 (93.8)
Any serious adverse event 4 (9.1) 7 (21.9)
Any adverse event causing
discontinuation
1 (2.3) 1 (3.1)
Adverse events by preferred term, n (%)a
Fall 9 (20.5) 11 (34.4)
Urinary tract infection 9 (20.5) 8 (25.0)
Lower respiratory tract
infection
9 (20.5) 3 (9.4)
Contusion 5 (11.4) 6 (18.8)
Agitation 5 (11.4) 11 (34.4)
Anemia 4 (9.1) 5 (15.6)
Blood urea increased 4 (9.1) 3 (9.4)
Aggression 3 (6.8) 5 (15.6)
Edema peripheral 3 (6.8) 4 (12.5)
Cellulitis 3 (6.8) 3 (9.4)
Anxiety 2 (4.5) 2 (6.3)
Behavioral and psychiatric
symptoms of dementia
3 (6.8) 2 (6.3)
Blood potassium increased 2 (4.5) 3 (9.4)
aNumber of adverse events occurring in at least 5% of patients.15
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therapeutic benefit of pimavanserin on psychosis was associated with
an improvement in agitation and aggression symptoms on the
NPI-NH domain C score. Psychosis responders also exhibited an
improvement from baseline in CMAI-SF score at week six, although
the difference between responders and nonresponders was not statis-
tically significant. This may be explained by the relatively low patient
numbers in the severe subgroups and by a slight improvement in
CMAI-SF score for nonresponders between weeks four and six.
Improvement of psychosis was correlated with the improvement
of agitation and aggression at the study's primary endpoint, in both
the overall study population and those with severe agitation and
aggression at baseline, supporting the relationship between these two
types of symptoms in patients with AD. This correlation is consistent
with the observation that patients with severe psychosis symptoms at
baseline (NPI-NH psychosis score ≥ 12) in this study had higher agita-
tion and aggression scores than the overall population21 and with sev-
eral studies that have reported significant correlations between
psychosis and agitation and aggression in patients with dementia.27
Collectively, results described here suggest that the improvement
in hallucinations and delusions after pimavanserin treatment are
related to improvements observed in agitation and aggression.
Mechanisms driving agitation and aggression in AD remain under
investigation. However, evidence for unique patterns of underlying
brain circuit dysregulation suggests that distinct types of agitation and
aggression might require unique treatment approaches.17,28 Consis-
tent with this, AD patients in one study, exhibiting moderate agitation
symptoms, responded dramatically to citalopram treatment for the
management of agitation/aggression symptoms; however, in the same
study, those exhibiting severe agitation symptoms showed no thera-
peutic benefit from the same treatment.16 Our results suggest one
potential underlying mechanism of agitation and aggression in AD is
related to psychosis and that treating psychosis may provide a more
precise approach to treating agitation and aggression in these
individuals.
The current analysis was not prespecified and was conducted
post hoc. The analysis is further limited by the small sample sizes in
subgroups of pimavanserin-treated patients. The comparison of non-
randomized groups (psychosis responders and nonresponders) may be
a source of bias unaccounted for by the statistical modeling. In addi-
tion, the study was limited to AD patients in nursing homes in the
United Kingdom. Patients, in this study, were required to have psy-
chosis symptoms at baseline but were not recruited for the presence
of agitation and aggression, which may have limited the number of
patients with a potential for improvement in agitation and aggression.
Further research is needed to confirm the generalizability of these
results beyond the United Kingdom, in other subtypes of dementia
and in patients recruited for the presence of agitation and aggression.
Safe and effective treatments to address symptoms of psychosis
and agitation and aggression are a critical unmet need in patients with
dementia. The primary endpoint analysis of the randomized clinical
trial demonstrated significant benefit in the treatment of psychosis at
6 weeks, with acceptable safety and tolerability over 12 weeks of
treatment in patients with ADP.15,21 The current analysis indicates
additional benefits in the treatment of agitation and aggression among
participants with a therapeutic response in the treatment of
psychosis.
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